Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

NCT00466232 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Carcinoma
Lung Cancer

Interventions

DRUG: Topotecan
DRUG: Sorafenib

Sponsor

HealthPartners Institute